Valuation: Steminent Biotherapeutics Inc.

Market Cap 15.11B 461M 413M 378M 345M 650M 43.32B 670M 4.55B 1.82B 23.11B 1.73B 1.69B 72.97B P/E 2024
-8.1x
P/E 2025 -20.4x
Enterprise Value 14.68B 448M 402M 367M 335M 631M 42.1B 651M 4.42B 1.76B 22.46B 1.68B 1.64B 70.91B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
58.85%
Yield 2024 *
-
Yield 2025 -
1 day-1.83%
1 week+5.93%
Current month+5.93%
1 month-4.82%
3 months+142.56%
6 months+147.04%
Current year+211.98%
1 week 161.5
Extreme 161.5
203
1 month 161.5
Extreme 161.5
204.5
Current year 51.4
Extreme 51.4
240
1 year 38.15
Extreme 38.15
240
3 years 15.25
Extreme 15.25
240
5 years 15.25
Extreme 15.25
240
10 years 15.25
Extreme 15.25
240
Manager TitleAgeSince
Chief Executive Officer - 26/11/2018
Director of Finance/CFO - 15/09/2021
Investor Relations Contact - 01/10/2023
Director TitleAgeSince
Director/Board Member 54 08/12/2021
Director/Board Member - 15/09/2020
Chairman - 26/01/2024
Change 5-day change 1-year change 3-year change Capi.($)
-1.83%+5.93%+377.10% - 461M
-4.83%+3.51%+55.00%+63.79% 66.7B
+0.02%+1.07%+11.72%+75.63% 56.88B
-1.34%+2.98%+25.08%+100.18% 56.53B
+5.09%+9.89%+27.19%+105.85% 46.49B
+2.62%+1.68%+29.16%+35.86% 44.8B
+8.24%+0.51%+215.16%+794.74% 41.59B
-1.86%+10.13%+28.14%+55.48% 35.35B
-2.97%-9.84%+90.91%+73.49% 33.29B
+5.19%+1.62%-39.69%+368.87% 25.1B
Average +0.83%+2.57%+81.98%+185.99% 40.72B
Weighted average by Cap. +0.65%+3.07%+50.27%+165.88%

Financials

2024 2025
Net sales - -
Net income -159M -4.84M -4.34M -3.97M -3.62M -6.83M -455M -7.04M -47.84M -19.08M -243M -18.17M -17.78M -767M -174M -5.31M -4.76M -4.35M -3.97M -7.48M -499M -7.72M -52.45M -20.91M -266M -19.92M -19.5M -841M
Net Debt -153M -4.67M -4.19M -3.83M -3.5M -6.59M -439M -6.8M -46.17M -18.41M -234M -17.54M -17.17M -740M -426M -12.99M -11.65M -10.65M -9.72M -18.31M -1.22B -18.89M -128M -51.17M -651M -48.75M -47.7M -2.06B
Projected Income Statement - Annual - Steminent Biotherapeutics Inc.
Logo Steminent Biotherapeutics Inc.
Steminent Biotherapeutics Inc is a Taiwan-based trading company mainly engaged in the research and development of new stem cell drugs and the development of allogeneic mesenchymal stem cell technology platforms. The Company's main product is the new stem cell drug product Stemchymal. The new stem cell drug product Stemchymal is used to treat spinocerebellar ataxia, Huntington's disease, acute ischemic stroke, acute inflammatory indications and other diseases.
Employees
-
Date Price Change Volume
06/11/26 TWD 187.50 -1.83% 1,104,050
05/11/26 TWD 191.00 +1.33% 842,499
04/11/26 TWD 188.50 -4.80% 937,767
03/11/26 TWD 198.00 +7.61% 1,552,515
02/11/26 TWD 184.00 +3.95% 1,047,865
  1. Stock Market
  2. Stocks
  3. 7729 Stock